CA-HILLSTONE-NETWORKS
24.1.2023 08:01:36 CET | Business Wire | Press release
Hillstone Networks, a leading provider of innovative and accessible cybersecurity solutions, has announced a major upgrade to its operating system, Hillstone StoneOS 5.5R10. The latest upgrade delivers AI-based high performance threat protection, centralized Zero Trust control and management, and further simplification of security operations and system optimization, among over 300 new features. The new functionality enhances the security posture of customer environments and further streamlines security operations with an easy upgrade path.
Threat protection enhancements with AI technology
The new StoneOS leverages AI technology to provide ML-based threat detection for encrypted traffic without the need for decryption. It also features intelligent DDoS protection and DGA detection. In addition, included is a blacklist extension that empowers the Perimeter Traffic Filtering (PTF) function and delivers more protection against threats.
Centralized Zero Trust control and management
Advanced ZTNA implements centralized management for ZTNA policies through Hillstone Security Management (HSM), and supports intelligent connection to ZTNA gateways, single packet authentication (SPA), multiple vendor Operating System support for ZTNA clients, along with a ZTNA portal. The new features provide a better user experience with improved overall operations and management of the ZTNA solution.
Smarter interconnectivity with extended VPN capabilities
The extended VPN features support ECMP and failover for intelligent VPN routing and provide IPSec VPN tunnel establishment options by configuring custom ports and auto-negotiation. These features bring better bandwidth utilization and improve connectivity, ensuring the business remains undisrupted.
Streamlined system operations offload redundant workloads
The latest StoneOS introduces a simplified start-up wizard and automated NAT redundancy check to facilitate system operations, improving overall productivity for organizations by streamlining the workload of system administrators.
Robust system-wide enhancements further ensure business continuity
System availability is improved across the board in the latest release, with support for advanced High Availability (HA) and the graceful restart of Border Gateway Protocol (BGP), further ensuring that business services remain uninterrupted for organizations.
“The transition from the traditional, edge-based security model to the distributed workforce model is a seismic change, triggered primarily by the pandemic-induced work from home mandate, but the impact will evolve gradually, and therefore the solutions we deliver need to address the associated challenges,” states Tim Liu, CTO and co-founder, Hillstone Networks, “The latest iteration of StoneOS continues to address the challenges faced by SecOps teams, and the constant risks faced by enterprises globally. Enhanced AI-driven threat protection, better integration, centralized control and management, and streamlined operations are all critical in delivering a stable and strategic approach to cyber-resilient cybersecurity environments.”
StoneOS is the foundation for all Hillstone next-generation firewalls, which has been recognized in the 2022 Gartner® Magic Quadrant™ for Network Firewalls for the 9th consecutive year as a Visionary. StoneOS 5.5R10 is now generally available.
About Hillstone Networks
Hillstone Networks’ innovative and accessible cybersecurity solutions reshape enterprise security, enabling cyber resilience while lowering TCO. By providing comprehensive visibility, superior intelligence, and rapid protection to see, understand, and act against multilayer, multistage cyber threats, Hillstone is favorably rated by leading analysts and trusted by global companies. To learn more visit www.hillstonenet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom